![](/images/graphics-bg.png)
Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
Joint Authors
Sun, Jin-Lu
Guan, Mei
Zhou, Yan-Ping
Chen, Shu-Chang
Source
Issue
Vol. 2015, Issue 2015 (31 Dec. 2015), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2015-05-05
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients.
Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid malignancies has continued to expand, currently encompassing a stunning amount of 20 distinct molecules for 11 targets.
We provide a brief scientific background on the use of MoAbs in cancer therapy, review all types of monoclonal antibodies-related adverse events (e.g., allergy, immune-related adverse events, cardiovascular adverse events, and pulmonary adverse events), and discuss the mechanism and treatment of adverse events.
American Psychological Association (APA)
Guan, Mei& Zhou, Yan-Ping& Sun, Jin-Lu& Chen, Shu-Chang. 2015. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International،Vol. 2015, no. 2015, pp.1-13.
https://search.emarefa.net/detail/BIM-1055453
Modern Language Association (MLA)
Guan, Mei…[et al.]. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International No. 2015 (2015), pp.1-13.
https://search.emarefa.net/detail/BIM-1055453
American Medical Association (AMA)
Guan, Mei& Zhou, Yan-Ping& Sun, Jin-Lu& Chen, Shu-Chang. Adverse Events of Monoclonal Antibodies Used for Cancer Therapy. BioMed Research International. 2015. Vol. 2015, no. 2015, pp.1-13.
https://search.emarefa.net/detail/BIM-1055453
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1055453